<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00599989</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000581427</org_study_id>
    <secondary_id>UPCC-08104</secondary_id>
    <secondary_id>UPCC-IRB-801897</secondary_id>
    <nct_id>NCT00599989</nct_id>
  </id_info>
  <brief_title>Partial Breast Radiation Therapy in Treating Women Undergoing Breast Conservation Therapy for Early-Stage Breast Cancer</brief_title>
  <official_title>Accelerated Partial Breast Irradiation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying the side effects of partial breast radiation therapy&#xD;
      and how well it works in treating women undergoing breast conservation therapy for&#xD;
      early-stage breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To allow women undergoing breast conservation therapy for early-stage breast cancer to&#xD;
           have access to accelerated partial breast irradiation therapy on a controlled trial.&#xD;
&#xD;
        -  To capture prospective data on acute and late toxicity and disease recurrence in&#xD;
           patients treated with this therapy.&#xD;
&#xD;
        -  To summarize the institutional experience of these patients treated with this&#xD;
           experimental therapy.&#xD;
&#xD;
      OUTLINE: Within 9 weeks after surgery, patients undergo accelerated partial breast&#xD;
      irradiation (including conformal external-beam irradiation, interstitial brachytherapy,&#xD;
      intracavitary brachytherapy, or proton beam irradiation) twice daily for 5 days (10&#xD;
      fractions).&#xD;
&#xD;
      After completion of study therapy, patients are followed every 3 to 6 months for at least 5&#xD;
      years and then annually thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">May 11, 2009</completion_date>
  <primary_completion_date type="Actual">May 11, 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute toxicity as assessed by NCI CTC at 1 week, 4 weeks, and 3 months after completion of study therapy</measure>
    <time_frame>11 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Late toxicity and cosmesis as assessed at or before 3 years from the start of radiotherapy and every 3 months during follow-up</measure>
    <time_frame>11 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Site of disease recurrence (i.e., local, regional, or distant)</measure>
    <time_frame>11 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence</measure>
    <time_frame>11 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to locoregional recurrence</measure>
    <time_frame>11 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Long-term Effects Secondary to Cancer Therapy in Adults</condition>
  <condition>Skin Reactions Secondary to Radiation Therapy</condition>
  <arm_group>
    <arm_group_label>APBI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
    <arm_group_label>APBI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
    <arm_group_label>APBI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>3-dimensional conformal radiation therapy</intervention_name>
    <arm_group_label>APBI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>brachytherapy</intervention_name>
    <arm_group_label>APBI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>intracavitary balloon brachytherapy</intervention_name>
    <arm_group_label>APBI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>proton beam radiation therapy</intervention_name>
    <arm_group_label>APBI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Women who have chosen to undergo breast conservation therapy, including lumpectomy and&#xD;
             breast irradiation, at the University of Pennsylvania for any invasive mammary&#xD;
             carcinoma or intraductal breast cancer&#xD;
&#xD;
          -  Stage I-II invasive or intraductal breast cancer&#xD;
&#xD;
               -  Unifocal tumor ≤ 3.0 cm in size&#xD;
&#xD;
                    -  Patients with microscopic multifocality are eligible provided total&#xD;
                       pathologic tumor size is ≤ 3 cm&#xD;
&#xD;
               -  No proven multicentric carcinoma in more than 1 quadrant or separated by 4 or&#xD;
                  more centimeters&#xD;
&#xD;
                    -  Pre- or post-biopsy ipsilateral* breast MRI negative for multicentric&#xD;
                       disease (i.e., areas of cancer that cannot be removed in a single excision&#xD;
                       specimen) or other suspicious findings NOTE: *Patients with synchronous&#xD;
                       bilateral breast cancers who will be treated with radiotherapy to each&#xD;
                       breast are eligible, provided such treatment can be performed in a manner&#xD;
                       that avoids overlap between treatment fields. Both sides may be treated with&#xD;
                       partial breast irradiation (PBI) if the pathologic eligibility criteria are&#xD;
                       met for both tumors, or only one side may be treated with PBI if the&#xD;
                       criteria are met for only one tumor.&#xD;
&#xD;
               -  Negative margins of excision (≥ 2 mm) OR no tumor seen in a re-excision specimen&#xD;
&#xD;
               -  No extensive intraductal component present&#xD;
&#xD;
               -  Negative sentinel lymph node (SLN) or axillary lymph node dissection OR fewer&#xD;
                  than 4 positive nodes on adequate axillary lymph node dissection (i.e., 10 or&#xD;
                  more lymph nodes removed)&#xD;
&#xD;
                    -  If a SLN is positive on hematoxylin and eosin (but not by&#xD;
                       immunohistochemistry alone), complete axillary lymph node dissection is&#xD;
                       required&#xD;
&#xD;
                         -  Axillary lymph node staging is not required for patients with ductal&#xD;
                            carcinoma in situ&#xD;
&#xD;
                    -  No SLN identified in the internal mammary nodes&#xD;
&#xD;
                    -  No node &gt; 2 cm&#xD;
&#xD;
                    -  No node with extracapsular extension&#xD;
&#xD;
          -  Surgical clips placed in the operative bed OR ability to visualize operative bed on CT&#xD;
             scan of the breast&#xD;
&#xD;
               -  Target lumpectomy cavity/whole breast reference volume must be ≤ 30% based on the&#xD;
                  treatment planning CT scan&#xD;
&#xD;
          -  No diffuse calcifications on diagnostic mammogram&#xD;
&#xD;
               -  Negative post-biopsy mammogram required if presented with mammographically&#xD;
                  detected microcalcifications&#xD;
&#xD;
          -  Hormone receptor status unspecified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Menopausal status not specified&#xD;
&#xD;
          -  History of non-breast malignancies allowed provided patients have been disease free&#xD;
             for 5 or more years prior to randomization and are deemed by their physician to be at&#xD;
             low risk for recurrence&#xD;
&#xD;
               -  Treated carcinoma in situ of the cervix, carcinoma in situ of the colon, melanoma&#xD;
                  in situ, or basal cell and squamous cell skin cancer within the past 5 years&#xD;
                  allowed&#xD;
&#xD;
          -  Patients must agree to undergo breast MRI&#xD;
&#xD;
          -  No contraindication to MRI, including a pacemaker or other foreign body&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  No technical impediment to appropriate dosimetry&#xD;
&#xD;
          -  No personal history of collagen vascular disease&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior in-field irradiation&#xD;
&#xD;
          -  No presence of breast implant&#xD;
&#xD;
          -  No breast reconstructive surgery prior to study entry&#xD;
&#xD;
          -  No prior neoadjuvant chemotherapy or hormonal therapy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lilie Lin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>January 11, 2008</study_first_submitted>
  <study_first_submitted_qc>January 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2008</study_first_posted>
  <disposition_first_submitted>April 6, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>April 6, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 9, 2020</disposition_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>long-term effects secondary to cancer therapy in adults</keyword>
  <keyword>skin reactions secondary to radiation therapy</keyword>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>invasive lobular breast carcinoma with predominant in situ component</keyword>
  <keyword>invasive lobular breast carcinoma</keyword>
  <keyword>comedo ductal breast carcinoma</keyword>
  <keyword>ductal breast carcinoma in situ</keyword>
  <keyword>invasive ductal breast carcinoma</keyword>
  <keyword>medullary ductal breast carcinoma with lymphocytic infiltrate</keyword>
  <keyword>mucinous ductal breast carcinoma</keyword>
  <keyword>papillary ductal breast carcinoma</keyword>
  <keyword>tubular ductal breast carcinoma</keyword>
  <keyword>Paget disease of the breast with intraductal carcinoma</keyword>
  <keyword>Paget disease of the breast with invasive ductal carcinoma</keyword>
  <keyword>breast cancer in situ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

